EBioMedicine 63:103202 Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K, LEAN trial team, Abouda G, Aldersley MA, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hbscher SG, Newsome PN, (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
The categorys seasonality is beginning to resemble beer and spirits, while lower-dose 6-10 mg THC offerings are gaining share
Therefore, the existing safety evidence is insufficient to support pharmaceutical approval
Clinical use: Supervised protocols at medical clinics involve subcutaneous injection over 4 to 8 weeks, with dosing individualized to injury type and severity
They are single-ingredient, gluten-free, soy-free, and non-GMO
As a retired associate professor of pharmacy and clinical pharmacist who developed pharmacist driven medication prescribing clinics in our state's largest university teaching hospital outpatient geriatric & chronic noncancer pain (CNCP) clinics, allow me to say that for patients my age (70yo) & older, I believe that chronic opioid therapy for CNCP is a safer alternative than chronic NSAID therapy
